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A microfluidic approach to rescue 
ALS motor neuron degeneration 
using rapamycin
Phaneendra Chennampally1,4, Ambreen Sayed‑Zahid2,3, Prabakaran Soundararajan3, 
Jocelyn Sharp3, Gregory A. Cox2,3*, Scott D. Collins1,2,4 & Rosemary L. Smith1,2,5
TAR DNA‑binding protein‑43 (TDP‑43) is known to accumulate in ubiquitinated inclusions of 
amyotrophic lateral sclerosis affected motor neurons, resulting in motor neuron degeneration, loss 
of motor functions, and eventually death. Rapamycin, an mTOR inhibitor and a commonly used 
immunosuppressive drug, has been shown to increase the survivability of Amyotrophic Lateral 
Sclerosis (ALS) affected motor neurons. Here we present a transgenic, TDP‑43‑A315T, mouse model 
expressing an ALS phenotype and demonstrate the presence of ubiquitinated cytoplasmic TDP‑43 
aggregates with > 80% cell death by 28 days post differentiation in vitro. Embryonic stem cells from 
this mouse model were used to study the onset, progression, and therapeutic remediation of TDP‑
43 aggregates using a novel microfluidic rapamycin concentration gradient generator. Results using 
a microfluidic device show that ALS affected motor neuron survival can be increased by 40.44% in a 
rapamycin dosage range between 0.4‑1.0 µM.
Motor Neurons (MNs) are specialized excitable cells whose somas reside strictly within the motor cortex or 
spinal cord. These neurons develop axons projecting to other MNs or remote peripheral effector organs, most 
notably muscles, and glands. As such, MNs carry a significant responsibility for nominal organismal control 
and function. Amyotrophic lateral sclerosis (ALS) is a singularly debilitating MN disease with an onset at either 
a single or multiple sites (limbs, bulbar or upper motor cortex) and progresses over time to other sites causing 
degeneration of both upper and lower motor neurons eventually leading to muscle atrophy and  death1.
Superoxide dismutase 1 (SOD1), a protein  misfolding2 enzyme, is one of the earliest definitive ALS genes 
identified in  19933 and along with TAR DNA-binding protein-43 (TDP-43) aggregate formation in the  cytoplasm4 
are a common defining hallmark of ALS in both familial and sporadic pathologies. Currently, about 217 variants 
from point mutations spanning the SOD1 amino acid sequence have been identified in relation to  ALS5 (ALSoD).
The mechanisms of TDP-43 aggregate formation in ALS are well  documented6. Aggregate formation varies 
from patient to patient but is associated with abnormal C-terminal TDP-43  fragment7,8 or post-translational 
protein modification such as  ubiquinitation9,10,  phosophorylation11,12 and/or  acetylation13,14 of the TDP-43 pro-
tein, resulting in disruption/mutation of the nuclear import signal of TDP-4315,16. It is commonly accepted that 
ALS mediates TDP-43 depletion from the nucleus with a concurrent accumulation of ubiquitinated cytoplasmic 
 inclusions17, resulting in a loss of TDP-43 function as a nuclear protein as well as concurrent cytoplasmic toxicity 
resulting from mislocated TDP-4318–20. Recent studies suggest that TDP-43 mediated  toxicity21 proceeds through 
recruitment and agglutination of RNA-binding proteins along with components of the ubiquitin–proteasome 
and autophagy-lysosome  systems22. Another DNA binding protein mislocalization associated with familial ALS 
pathology is Fused In Sarcoma (FUS)23,24. FUS, a nuclear protein, has been associated with transcription, DNA 
repair  processes25,26 and RNA  metabolism27. However, the definitive reason for the mislocalization of the FUS 
protein is still inconclusive. Overall, mislocalized cytoplasmic TDP-4328 and  FUS29 can be used as pathological 
disease markers of ALS.
A transgenic ALS mouse model with TARDBP mutation (TDP-43 A315T) was used in the current study. 
Although the use of approved human ES cell lines is becoming increasingly popular, a murine model was adopted 
here and carries significant advantages such as considerable in vitro data for experimental designs, ease of avail-
able markers and similar development pathway to that of humans. Though murine cell line has above listed 
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advantages, it also has few limitations such as transgene overexpression or  upregulation30 in mouse compared to 
human models and failure of pharmaceutical  drugs31 in clinical trials though being successful in mouse models.
Rapamycin, or sirolimus, has been suggested as a potential therapeutic remediation for  ALS32,33, and is widely 
used to inhibit mTOR signaling (the mechanistic target for rapamycin). The mTOR intracellular protein kinase 
complex is involved in a host of critical cellular processes, including protein synthesis, lipid synthesis, prolifera-
tion, and  autophagy34–36. Autophagy is an essential cellular housekeeping function in which misfolded proteins 
and dead organelles are cleared from the cell. The mTOR complex, particularly the mTORC1 complex, inhibits 
autophagy through autophagy initiating kinase (ULK1) and ancillary downstream  targets37. Rapamycin inhibits 
mTOR/mTORC1 signaling  pathways38 subsequently activating  autophagy39 and promoting abnormal protein 
clearing, including TDP-43 aggregates. Rapamycin inhibition of the mTOR pathways also activates lysosomal 
 biogenesis40. Mandrioli et al. noted that rapamycin combined with riluzole, a glutamate blocker, can clear the 
cytoplasmic TDP-43 aggregates through induced  autophagy32. In support of this, Kamm et al.41, using a micro-
fluidic platform, reported that rapamycin produced increased muscle contractions in ALS derived motor units 
suggesting rapamycin as a potential ALS therapeutic.
Microfluidics has recently surfaced as an invaluable technique for cell culturing. One of the more significant 
advancements in microfluidics came with the advent of the concentration gradient generator, originally proposed 
by  Whitesides42 and significantly refined by  Demers43,44. Not only do gradient generators provide more facile, 
realistic, and meaningful bio environments for cellular studies, they can also provide custom spatial and temporal 
landscapes mimicking complex in vivo environments. This is a unique advantage of microfluidic systems that is 
not easily available using traditional cell plating techniques and therefore they provide a meaningful answers to 
previously intractable biological  questions43,45. Microfluidics has since been incorporated successfully in many 
cell culture applications, including single-cell analysis, developmental studies, pharmacologic interventions, 
and precision  medicine46–48. Here we recruit microfluidics to generate a linear rapamycin concentration gradi-
ent across a 3D MN culture and map the permissive zones of MN survival to evaluate the efficacy of rapamycin 
therapeutics in ALS. The results are compared with traditional 2D MN cultures.
Results & discussion
ALS is clinically characterized by a general MN degeneration resulting in axonal retraction and pruning, even-
tually causing muscle atrophy and death. Cytoplasmic mislocalization of TDP-43 and FUS aggregates have 
been identified as biomarkers in familial  ALS49 and are convenient metrics to investigate ALS pathology in MN 
cultures. In this study, a transgenic mouse model carrying the TDP-43-A315T (TARDBP) ALS phenotype was 
derived by crossing B6.Cg-Tg (Prnp-TARDBP*A315T) 95Balo/J mice with B6.Cg-Tg (Hlxb9-GFP)1Tmj/J mice 
(The Jackson Laboratories, JAX).The ES cells derived from this mutant line were differentiated into MNs in vitro 
and used to test the efficacy of rapamycin in rescuing the ALS phenotype.
Characterization of motor neurons for ALS pathology. All MNs were cultured from embryonic stem 
cells (ES cells) containing an enhanced green fluorescent protein (eGFP) marker that is expressed under the 
control of the Hb9::GFP reporter gene to unequivocally identify differentiated MNs. ES cells containing only 
the GFP marker with no ALS mutation were cultured as control cells. Manifestation of an ALS phenotype in the 
TDP-43-A315T (TARDBP) mutant cell line was demonstrated by assaying the mutant MNs for TDP-43 cytosolic 
mislocalization. Stem cells were differentiated into MNs in a 2D culture and immunocytochemically stained for 
TDP-43 and ubiquitin at 7 days, 14 days , 21 days and 28 days in vitro (DIV) (Fig. 1a–d). As expected, nuclear 
TDP-43 expression was found in both mutant MNs (Fig. 1) and control MNs (Fig. 2) throughout development, 
while cytoplasmic TDP-43 aggregates appeared only in the mutant strain and only after 14 DIV (arrows; Fig. 1b–
d). Ubiquitin showed diffuse expression for both mutant and control MNs, but was over expressed in mutant 
MNs at regions near, but outside the nucleus. These regions of over expressed cytosolic ubiquitin (arrows) were 
co-localized with cytosolic TDP-43 aggregates indicating possible ubiquitination of TDP-43 resulting in the 
formation of pathological TDP-43 aggregates. 
It appears that all cultures demonstrated healthy development at initial MN stages, i.e. without any cyto-
plasmic TDP-43 agrregates, but mutant cell line progressed to a disease phenotype post 7DIV. Interestingly, the 
degree of nuclear TDP-43 expression in mutant and control MNs was similar with no sign of nuclear clearance, 
indicating a dependable role in carrying out transcriptional regulation and other nuclear  functions50 despite the 
mislocalization of TDP-43. This is consistent with a recent study by Burkhardt et al.51 where human induced 
pluripotent stem cell-derived motor neurons carrying the TDP-43-A315T mutation maintained nuclear expres-
sion of TDP-43 while still demonstrating an ALS disease phenotype.
At 28 DIV we observed increased dendritic pruning and axonal  retraction52,53 of mutant MNs (Compare 
Fig. 1d with Fig. 2d). There was also a correspondingly sharp increase in MN mortality for mutant MNs with 
only an 8.7 ± 5.7% survival at 28 DIV as compared to control MNs, 58.5 ± 16.2% survival at 28 DIV (p ≤ 0.001, 
n ≥ 3, with a two-way ANOVA-sidak comparison) (Fig. 3a). Additionally, control ES cell-derived motor neurons 
retained normal cell morphology, dendritic projections and nuclear TDP-43 expression (Fig. 2a–d) with complete 
absence of cytoplasmic TDP-43 or  ubiquitin+ aggregates (Figure S5).
The overall MN viability was plotted as a function of culturing time days in vitro, for both mutant and con-
trol cells (Fig. 3a). As anticipated, the mutant cell line demonstrated a steep monotonic mortality through 28 
DIV while the control cell line showed higher viability. The decrease in  GFP+ control MNs by 28 DIV compared 
to 7 DIV (Fig. 3a) can be attributed to normal cell losses over time due to cell reprogramming, apoptosis, etc. 
occurring during normal cell development whereas the increased mutant mortality can be attributed to TDP-43 
cytosolic toxicity imposed by the ALS phenotype. We also identified a linear increase (p ≤ 0.05, n = 10) in the 
average number of cytosolic  ubiquitin+/TDP-43+ aggregates in the mutant line with time, correlating to mutant 
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MN mortality (Fig. 3b). Further investigation showed a nominal size distribution with the cytosolic aggregates. 
The cytosolic TDP-43+/ubiquitin+ aggregates were categorized (Fig. 3c) into small (1–2 µm), medium (2–4 µm), 
and large (> 4 µm) aggregates. Figure 3d shows that there is an increase in the medium and large cytosolic TDP-
43/ubiquitin aggregates at 21DIV and 28DIV in the mutant cell line presumably resulting from saturation and 
suggesting a potential interruption in the protein transport system.
FUS  aggregates23,24 are another common protein mislocalization associated with the pathophysiology of 
familial ALS. However, the cause and action of FUS cytosolic mislocalizations are somewhat more ambiguous 
than TDP-4323,49. To determine whether mutant cell lines also show any FUS mislocalizations, we immunocy-
tochemically stained mutant MNs for FUS and identified that 32.2 ± 34.8% (n ≥ 5) of cytoplasmic aggregates 
expressing TDP-43/Ubiquitin also expressed FUS (arrowed in Fig. 4a). Though this does not categorically identify 
the presence of a mutant gene or the cause of FUS mislocalization, it does indicate the presence of mislocalized 
cytoplasmic FUS protein along with TDP-43 and suggests a common aberrant biochemical pathway.
To validate that TDP-43 protein mislocalization resulted from the TARDBP mutation and not from an arbi-
trary ancillary effect, FLAG-Tag was used. FLAG-Tag is a polypeptide protein sequence added to the end of a 
targeted protein sequence, in this case at the end of the TDP-43 mutant gene sequence. FLAG is concurrently 
expressed with the associated TDP-43 gene and serves as a “tag” for TDP-43 expression (Fig. 4b). We found that 
in mutant MNs, FLAG also co-deposits with TDP-43/Ubiquitin cytoplasmic aggregates (arrowed in Fig. 4b), 
suggesting that the cytoplasmic TDP-43 aggregates were formed as a result of the expression of the TDP-43 tagged 
gene construct and not due to the native mouse TDP-43 expression. From western blot analysis (Figure S6a-d) we 
can confirm that the transgenic TDP-43 detected with the FLAG antibody was expressed only in mutants and not 
in control MNs (relative to β-tubulin) throughout the differentiation. Moreover, western blot analysis indicates 
that not only is there a decrease in total TDP-43 expression over time (both in control and mutant cells) but also 
the total TDP-43 expression in mutants is always lower than the control cells thereby ruling out the possibility 
of over-expression of the transgenic protein to be the cause of disease phenotype.
To rule out the possibility that the observed mutant phenotype was clone specific, we differentiated ES cells 
from a second independent mutant clone into motor neurons. As expected, we discovered that ES cell-derived 
Figure 1.  Immunocytochemical analysis of mutant MNs. Mutant MNs show the presence of both nuclear 
TDP-43 (pink arrows) and co-localized cytoplasmic TDP-43/ubiquitin aggregates (white arrows) at 7,14, 21 and 
28 DIV (a–d). Massive dendritic pruning and axonal retraction in mutant MNs were observed at 28 DIV (d), 
indicating the onset of MNs degeneration. No disease phenotype was manifested at 7DIV in mutant cells (a). 
The MN nuclei can be identified from the large regions of TDP-43 staining.
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motor neurons from the second clone with the TDP-43-A315T transgene also formed cytoplasmic aggregates 
that stained positive for both TDP-43 and ubiquitin, confirming that the cytoplasmic aggregates are due to the 
introduced transgene (Figure S2).
Taken together, this indicates that the mutant ALS phenotype cell line we generated strongly expresses the 
characteristic features of familial ALS, sharing ubiquitinated TDP-43 cytoplasmic aggregates, and is therefore 
an ideal candidate for studies of ALS pathophysiology.
MN rescue using rapamycin. Protein aggregates are an important feature in ALS pathology and targeting 
them as a therapeutic treatment for ALS is a more  promising54 approach than the current approaches that focus 
on delaying progression of the disease. One of the more promising approaches is the use of mTOR inhibitors 
such as rapamycin to clear cytosolic aggregates of TDP-4332. In the following sections, we investigated the effi-
cacy of rapamycin to salvage ALS phenotypes.
Rapamycin treatment in a 2D culture. After fully differentiating both control and mutant ES cells into MNs 
for 7DIV using standard MN differentiation media, the cultures were then exposed to 1 µM rapamycin and 
MN viability was monitored at 14DIV, 21DIV and 28DIV. Mutant cells (ALS phenotype), treated with rapamy-
cin showed significantly improved MN survivability compared to the untreated mutant cells (e.g., comparing 
treated mutants vs. untreated mutants by 28 DIV, a 54.91 ± 5.67% increased MN survivability was observed 
with a p ≤ 0.001 & n ≥ 3 by two-way ANOVA-sidak test). In fact, rapamycin treated mutant MNs demonstrated 
essentially equivalent viability as untreated control MNs (e.g., by 28 DIV the difference in MN viability was only 
5.54 ± 16.9% with a p > 0.05 & n ≥ 3 by two-way ANOVA-sidak test) indicating that 1 µM rapamycin treatment 
is capable of fully rescuing ALS phenotypes (Fig. 5a, for detailed statistical analysis and comparison see sup-
plementary Sheet 1). Further examination of 1 µM rapamycin treated cells revealed the mitigation of cytosolic 
ubiquitinated TDP-43 aggregates (Fig. 5b). This is in direct contrast to the presence of the cytosolic aggregates in 
the untreated MNs (indicated by arrows).
Figure 2.  Immunocytochemical analysis of control MNs. Control MNs show the presence of only nuclear TDP-
43 aggregates (arrows) and without any cytoplasmic aggregates of TDP-43/ubiquitin at 7DIV (a), 14DIV (b), 
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Rapamycin treatment in a 3D culture. The above experiments effectively demonstrate the potential of rapa-
mycin to rescue the ALS MN phenotypes. However, recent  reports55 suggest that traditional 2D cell plating in a 
homogenous media may fail to fully reproduce a true in vivo environment. In contrast, 3D cell cultures generally 
preserve inherent morphological and phenotypical cell development and growth more faithfully. To ameliorate 
deficiencies imposed by 2D cell cultures, a number of successful 3D culturing techniques have surfaced, most 
notably embryoid bodies, gel matrices and scaffolding. Here we adopt a microfluidic approach to generate rapa-
mycin concentration gradients within a 3D gel matrix and evaluate the permissive growth zones for the ALS 
phenotype as a function of the spatial rapamycin concentration. This microfluidic approach enables a rich exper-
imental platform that not only facilitates faster, more robust and faithful developmental and drug testing, but 
more importantly, enables uniquely new experimentational venues for exploration. Yet, a significant drawback 
to the microfluidic approach is an inability to obtain high resolution micrographs of subcellular geometries due 
to inherent light scattering and absorptive effects in thick, multilayers cellular samples that are firmly ensconced 
in an extracellular matrix. For this reason, we employed traditional 2D culturing to clearly visualize subcellular 
features, while capitalizing on the facile, quick and contextually relevant 3D environment of microfluidics to 
provide a more detailed and comprehensive investigation into ALS: its cause and its remediation.
Characterization of microdevice. A full explanation outlining the generation of 3D concentration gradients 
is presented in Demers.et.al43,44. In brief, a traditional source/sink diffusion motif is employed to maintain a 
steady-state concentration profile across a cell culture. Rapamycin is introduced to one side of the microdevice 
cell chamber at a high constant concentration (source) and allowed to freely diffuse to a lower concentration 
(sink) on the opposite side of the microdevice cell chamber (Figure S3a). For 1D diffusion at steady state, this 
results in a linear rapamycin concentration across the microdevice cell chamber from source to sink. This spatial 
gradient is then used to assess ALS cells viability at different positions (bin) within the gradient with each bin 
corresponding to a specific rapamycin concentration.
Figure 3.  MN viability & quantification of cytosolic TDP-43 aggregates. (a) In vitro, quantification of MN 
viability showed a rapid decrease in the number of mutant MNs carrying TDP-43 mutation from 7 to 28DIV 
compared to that of control MNs without the mutation (p ≤ 0.001,n ≥ 3). All fluorescent intensities were 
normalized to 100% at 7 DIV. (b) Total number of  Ubiquitin+/TDP-43+ aggregates per  GFP+ mutant MNs 
increased from 14 to 28DIV (n = 10,p ≤ 0.001) (c) Immunocytochemical staining of TDP-43 & Ubiquitin 
and their classification into different sizes in the mutant MNs  (GFP+). White arrows indicate the different 
sized cytosolic aggregates and pink arrows indicated the TDP-43 in the nucleus. (d) There is an increase in 
medium and large sized cytosolic TDP-43+/Ubiquitin+ aggregates in mutant MNs from 14 to 28DIV. P values: 
Non significant (ns)P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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Computational modeling of the rapamycin concentration profile was performed using COMSOL Multiphys-
ics, a finite element analysis program (Figure S3a) to assess and quantify gradient performance. Experimental 
confirmation of the in silico results were obtained by establishing a linear fluorescein concentration gradient 
across the gel filled chamber of the microdevice and quantifying the fluorescent profile by measuring the fluo-
rescent intensity at 520 nm (excitation 488 nm) as a function of distance across the chamber (Figure S3b). At 
short diffusion times, profiles followed normal Cottrell distributions that transitioned into a linear, steady-state 
gradient in about 10–20 min. The linear profiles were stable indefinitely, as long as the fluorescein concentrations 
Figure 4.  Validation of mutant TDP-43-A315T transgene as the source of cytosolic TDP-43 aggregates. (a) 
Immunocytochemical staining of mutant MNs. 32.2 ± 34.8% (n ≥ 5) of Mutant (A315T) cell-derived motor 
neurons also expressed FUS and co-localized with cytosolic ubiquitinated aggregates (indicated with arrows). 
(b) Immunocytochemical staining showing the cytosolic co-localized FLAG peptide with that of the TDP-43 
(indicated with arrows), validating the generation and presence of TDP-43 in the mutant cells is due to the 
mutant gene.
Figure 5.  Rapamycin assay in 2D culture. (a) Mutant (A315T) MNs show an increase in survival when 
treated with 1 µM of rapamycin with %GFP+ cells equivalent to those of control at 21DIV and 28DIV. Mutant 
MNs not treated with rapamycin show a rapid decrease in survival from 7 to 28DIV compared to the control 
MNs(Untreated Control). All fluorescent intensities were normalized to 100% at 7 DIV. (b) Immunostaining of 
treated and untreated mutant MNs for cytosolic TDP-43 and Ubiquitin showing the reduction/absence of the 
cytosolic aggregates in the treated samples compared to that of untreated samples (arrows are indicating the 
cytosolic aggregates). P values: Non significant (ns)P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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at the two boundaries (source and sink) were continually refreshed with reagent flow from the microchannels, 
i.e., boundary concentrations kept constant (Figure S3b).
Rapamycin assay in the microdevice. ES cells, both control and mutant, were differentiated into MNs for 7 DIV 
in the microdevice using standard MN differentiation media according to protocols outlined in the methods 
Sect. (4.4). A MN cell identity was confirmed by expression of the Hb9::GFP reporter (eGFP). At 7DIV, the MNs 
were then exposed to a linear rapamycin gradient for the remaining duration of the experiment by introducing 
2 µM rapamycin into the source media and 0 µM rapamycin in the sink media. Immunostaining of MNs was 
carried out using anti-GFP and anti-TDP-43 antibodies at 14DIV and 21DIV (Figs. 6a & 7a). GFP was used as 
a marker for differentiated motor neurons and anti-TDP-43 was used to stain TDP-43 aggregates.  GFP+ fluores-
cent intensities were plotted as a function of rapamycin concentration, i.e., the spatial position in the microde-
vice. Intensities were averaged over five samples and normalized to eGFP fluorescent intensities at 7DIV, i.e. all 
average eGFP intensities at 7DIV were normalized to 100%.
By 14 DIV the untreated mutant MNs demonstrated a 24.4 ± 13.8% (p ≤ 0.001, n ≥ 4, two-way ANOVA-sidak 
test) lower viability than their untreated control MNs as indicated in Fig. 6b, 0 µM rapamycin. Again, a general 
loss of untreated MN viability with time is expected and attributed to normal cell losses during early MN devel-
opment and growth. It is encouraging that at 14DIV rapamycin treated mutant cells showed virtually complete 
rescue over all rapamycin concentrations when compared to the corresponding treated control MNs (Fig. 6b). 
This is also consistent with the absence of TDP-43 cytoplasmic aggregates in rapamycin treated 2D MN cultures 
(Fig. 5b). However, a general MN toxicity begins to emerge which is shown clearly in Fig. 6c. Here the relative 
percentage of viable control MNs as a function of rapamycin concentration is plotted for 14 DIV using the 
concentration of untreated control (0 µM rapamycin) as a reference, i.e. percent viability for rapamycin treated 
control MNs minus untreated control MNs. Generally, little to no rapamycin sensitivity is seen at low rapamycin 
concentration for shorter exposure times (≤ 14DIV), but for rapamycin concentrations > 1 µM, a small but notice-
able decrease in MN viability begins to emerge (e.g., comparing MN viability at 0.4 µM to 1.8 µM in Fig. 6c, a 
Figure 6.  Rapamycin assay in microdevice (14DIV). (a) Typical microdevice immunostaining for GFP and 
TDP-43 at 14DIV under a rapamycin gradient. Red sidebars immediately to the right indicate the spatial 
direction of the rapamycin gradient (red: 0 –2 µM) while the blue bars indicate a constant concentration of 
culture media morphogens. (b) Plots the average (n ≥ 4) percent viability of rapamycin treated MNs  (GFP+) i.e. 
viability of treated mutant MNs (red) and treated control MNs (green) as a function of rapamycin concentration. 
*Indicates both mutant and control MNs which are not exposed to rapamycin, i.e. untreated MNs respectively. 
(c) Shows the relative MN toxicity of rapamycin on control MNs, i.e. the percent viability of rapamycin treated 
control MNs minus the average viability of rapamycin untreated control MNs. A positive ( +) value indicates 
an increased survival of control MN’s without rapamycin and a negative (−) value indicates a toxicity effect of 
rapamycin. P values: Non significant (ns)P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
8
Vol:.(1234567890)
Scientific Reports |        (2021) 11:18168  | https://doi.org/10.1038/s41598-021-97405-1
www.nature.com/scientificreports/
21.47 ± 14.3% decrease in MN viability is observed, with a p ≤ 0.01 & n ≥ 4 by a two-way ANOVA-sidak test) and 
becomes more pronounced at longer rapamycin exposure times, see 21 DIV (Fig. 7c).
As cells progressed to 21DIV, it was not surprising to see a 42 ± 10.652% (p ≤ 0.001,n ≥ 4, two-way ANOVA-
sidak test) increase in mortality for untreated mutant MNs compared to the untreated control MNs (Fig. 7b, 0 µM 
rapamycin). However, several interesting trends also surfaced. First, low rapamycin concentrations (≤ 0.2 µM) 
were ineffectual in salvaging mutant MNs, most likely due to reduced inhibition of the mTOR pathways and/or 
suppressed TDP-43 clearing, resulting in significant TDP-43 cytoplasmic depositions. This is not surprising as 
most therapeutic drugs have threshold concentration limits, both high and low. Second, rapamycin concentra-
tions between 0.4 to 1.0 µM presented a permissive MN growth zone for both control and mutant MNs. Over this 
region rapamycin treated mutant MNs showed a dramatical increase in viability, 40.44 ± 11.12% (p ≤ 0.001, n ≥ 4, 
two-way ANOVA-sidak test) in comparison to untreated mutant MNs (Fig. 7b, 0 µM rapamycin), while control 
cells demonstrated little to no adverse effects from rapamycin exposure. Third, at high rapamycin concentra-
tions > 1.4 µM, control MNs experienced a substantial decrease in MN viability (e.g., comparing MN viability 
at 0.4 µM to 2.0 µM in Fig. 7c, a 26.1 ± 13.9% decrease in MN viability is observed, with a p ≤ 0.001 & n ≥ 4 by a 
two-way ANOVA-sidak test), indicating increased toxicity from 14 to 21DIV (Fig. 7c, compared with Fig. 6c, 
Sheet S1 for two-way ANOVA group comparisons), and while rapamycin treatment still salvaged mutant MNs 
from demonstrating the ALS phenotype, mutant MNs also showed a steady loss of viability at higher rapamycin 
concentrations (Fig. 7b, compare with Fig. 6b).
Nevertheless, comparing the TDP-43 aggregates per MN at different time interval (Fig. 3b) with an observed 
increase in untreated MN mortality from 2D (Fig. 5a) and 3D (Figs. 6a, 7a) MN cultures indicate a possibility 
that the cytosolic TDP-43 aggregates are related to the increased mortality in mutant MNs and rapamycin was 
able to rescue these mutant MNs from degeneration in both 2D and 3D cultures indicating a potential path for 
ALS remediation.
Figure 7.  Rapamycin assay in microdevice (21DIV). (a) Typical microdevice immunostaining for GFP and 
TDP-43 at 21 DIV under a rapamycin gradient. Red sidebars immediately to the right indicate the spatial 
direction of the rapamycin gradient (red: 0–2 µM), while the blue bars indicate a constant concentration of 
culture media morphogens. (b) Plots the average (n ≥ 4) percent viability of rapamycin treated MNs  (GFP+) i.e. 
viability of treated mutant MNs (red) and treated control MNs (green) as a function of rapamycin concentration. 
*Indicates both mutant and control MNs which are not exposed to rapamycin, i.e. untreated MNs respectively. 
(c) Shows the relative MN toxicity of rapamycin on control MNs, i.e. The percent viability of rapamycin treated 
control MNs minus the average viability of rapamycin untreated control MNs. A positive ( +) value indicates 
an increased survival of control MN’s without rapamycin and a negative (−) value indicates a toxicity effect of 
rapamycin. P values: Non significant (ns)P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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Conclusion
In this article mouse embryonic stem cells possessing the mutant human ALS TDP-43-A315T transgene were 
successfully derived and differentiated into MNs under both 2D and 3D environments to assess the efficacy of 
rapamycin as a rescue to the ALS phenotype. A traditional 2D cell culture does not fully represent a true in vivo 
environment, and a 2D assay is usually laborious and less economical. A 3D gradient  microfluidic56–58 assay 
overcomes these limitations but has its drawbacks such as, difficulty in achieving high resolution imaging to dif-
ferentiate intracellular components due to the dense 3D cell clusters. Therefore, by merging a traditional 2D cell 
culturing approach with a 3D microfluidic platform, we were able to combine the advantages inherent in both 
techniques (high-resolution 2D images with high-throughput 3D spatial titrations) to more comprehensively, 
accurately and quickly assay MN development and degeneration under appropriate pharmacological remediation 
(rapamycin). Using this combined approach, we demonstrated motor neurons from the mutant cell line showed 
cytosolic mislocalization of TDP-43 aggregates and FUS protein with ubiquitin co-deposition, representing the 
hallmark phenotypical ALS pathology. Moreover, it was confirmed that mislocalization of TDP-43 aggregates due 
to the mutant phenotype is not clone specific and occurs in other variants possessing the same ALS mutation. 
Additionally, we were able to show that TDP-43 mislocalization increases with culturing time and is correlated 
to cell mortality at later life cycles.
Using the microfluidic platform, we also demonstrated an optimal 40.44% rescue of the ALS phenotype over 
a concentration range of 0.4–1.0 µM. For lower rapamycin concentrations, the drug was ineffectual in rescuing 
the ALS phenotype while rapamycin demonstrated significant toxicity for higher concentrations and exposure 
times. This strongly suggests potential remediation of ALS is possible using mTOR inhibitors such as rapamy-
cin. An essential advantage to the microfluidic assay presented here is that an entire rapamycin titration was 
performed in a single cell culture experiment (with replicates), thereby greatly enhancing test throughputs and 
results. The small size of the device, 1 mm × 1 mm, allows for parallel testing of large device arrays increasing 
the testing throughput, thereby enabling drug discovery and screening, as well as patient-specific drug screen-
ing and treatment. Due to the intrinsic potential of the microfluidic device to differentiate cells in 3D and retain 
their spatial and morphological construct similar to in vivo, in future, a modified design of this current platform 
can be utilized in exploring and understanding axonal progression and degeneration over time in ALS cell lines 
(mESCs and human IPSCs) while performing a therapeutic screening/treatment.
Materials and methods
Derivation of transgenic (mutant) mouse embryonic stem cells. Embryonic stem (ES) cells pos-
sessing both ALS phenotype mutations in the TARDBP gene and a Hb9::GFP reporter were derived from cross-
ing B6.Cg-Tg (Prnp-TARDBP*A315T) 95Balo/J mice with B6.Cg-Tg (Hlxb9-GFP)1Tmj/J mice (The Jackson 
Laboratory, Bar Harbor, ME, USA (JAX)). Enhanced GFP (green fluorescence protein) is expressed under the 
control of the mouse Hb9 promoter, and thus, eGFP expression can be used to identify putative motor  neurons59. 
Following derivation, B6.Cg-Tg(Prnp-TARDBP*A315T) 95Balo/J:B6.Cg-Tg(Hlxb9-GFP) 1Tmj/J ES cells 
(referred to as mutant ES cells or mutant (A315T)) were cultured using standard ES cell media with 2 inhibitor 
supplements (2i)60. The ES cells were genotyped and following karyogram analysis, they were characterized with 
standard pluripotent markers (Figure S1a-b). Motor neurons differentiated from these cells are referred to as 
mutant MNs. Human mutant transgene is referred as TDP-43-A315T.
The ES cells obtained from B6.Cg-Tg (Hlxb9-GFP)1Tmj/J mice having only the Hb9::GFP reporter are 
referred to as control ES cells and differentiated MNs from these ES cells are referred to as control motor neurons. 
All these cell lines are isogenic as they were derived from littermates that are inbred strains of mice. The mice 
are > 99.99 percent identical as they are maintained on an inbred C57BL/6 J genetic background by a continuous 
brother, sister mating at The Jackson Laboratory. The mice used in the generation of the cell lines were treated in 
accordance with Animal Research: Reporting of In Vivo Experiment (ARRIVE) guidelines.
All mouse husbandry and procedures were reviewed and approved by the Institutional Animal Care and 
Use Committee at The Jackson Laboratory and were carried out according to the NIH Guide for Care and Use 
of Laboratory Animals (AUS# 01006).
Mutant and control motor neuron development. All embryonic stem cells were differentiated in MN 
differentiation  media61 and cultured at 37 °C under 5%  CO2. The MN differentiation media contained: Advanced 
DMEM/F12 and Neurobasal media in a 1:1 ratio supplemented with B2, N27, 5% heat-inactivate horse serum 
(Invitrogen), 10 ng/ml of CNTF, GDNF, BDNF, and NT-3 (R&D Systems), 3 µM sonic hedgehog agonist pur-
morphamine (Calbiochem, MilliporeSigma) and 1 µM retinoic acid (RA, Sigma).
The experimental protocol for the development of ALS MNs is generally divided into two independent pro-
cedures: (a) a traditional 2D culturing of motor neurons and (b) a 3D culturing of MNs in a fluidic microdevice. 
Using the appropriate 2D or 3D protocols, all ES cells were cultured for 7 days in vitro (DIV) in MN differentia-
tion media before exposing them to rapamycin. This time frame was sufficient to differentiate ES cells into MNs, 
as evidenced by Hb9::GFP expression.
2D culturing of ES cells into MNs. Embryonic stem cells were first grown to embryoid bodies for 3 days 
in MN differentiation media using standard embryoid body culturing  techniques62,63. Embryoid bodies were 
resuspended in fresh differentiation media and allowed to culture for an additional 2 days. Embryoid bodies 
were then collected and dissociated into single cells using papain (Worthington Kit). Dissociated cells were 
then plated on coverslips coated with reduced growth-factor Matrigel (BD Biosciences, Bedford, MA) and the 
individually coated coverslips were placed in a 24-well microtiter plate containing MN differentiation media and 
10
Vol:.(1234567890)
Scientific Reports |        (2021) 11:18168  | https://doi.org/10.1038/s41598-021-97405-1
www.nature.com/scientificreports/
allowed to grow. Dissociated cells were plated at a density of 20,000 cells/well. Motor neuron culture media was 
changed twice a week.
3D culturing of ES cells in the microfluidic device. Details of the microdevice construct and experi-
mental conditions are published in a previous  report43. Experimental parameters deemed necessary for com-
pleteness and/or analyzing the results are repeated here. Embryonic stem cells (Control or Mutant) were sus-
pended in Geltrex (Gibco, LDEV-Free, hESC-Qualified, Reduced Growth Factor Basement Membrane Matrix) 
at 4 °C at a density of  106–107 cells/ml. 0.3 µl of cell-ladened gel matrix was dispensed into the microfluidic 
device culture chamber and allowed to set by warming to 37 °C. Because of the small sample volume, both gel 
matrix cooling and heating could be performed within several seconds, minimizing stress to the ES cells.
Fluidic connections to the microdevice were immediately established to continuously perfuse the embry-
onic stem cells with the appropriate media (MN differentiation media and/or rapamycin). All media was pre-
equilibrated with air at 5%  CO2 and 37 °C.
Chemical gradient generation. Chemical gradient generation capability of the microdevice was vali-
dated using fluorescein according to previously published  procedure43. In brief, the microdevice cell chamber 
was loaded with Geltrex. Fluorescein (5 µM) was introduced to one fluidic channel of the microdevice, while 
DI water was introduced into the opposite microchannel. A concentration gradient was thereby established 
between the microchannels by diffusion of fluorescein (diffusion coefficient: 4.9 ×  10−6   cm2   s−1) from source 
to sink. The concentration profile of fluorescein generated in the cell chamber was captured using Zeiss Axio 
Observer Z1 inverted microscope and fluorescent emission intensities at 520 nm (excitation wavelength 488 nm) 
were mapped as a function of distance to verify the creation of a linear source/ sink concentration profile within 
the gel matrix (see Figure S3).
Therapeutic drug interventions (Rapamycin). By 7DIV, ES cells had developed into MNs as evidenced 
by expression of Hb9::GFP. At 7DIV, both 2-D and 3-D perfusion media were changed to include rapamycin. For 
2-D cultures, rapamycin (1 µM) was added directly to MN differentiation media and allowed to incubate in the 
24 well microtiter plate. For 3-D microfluidic cultures, a rapamycin diffusion gradient was established across the 
cell culture chamber by addressing one microfluidic channel with MN differentiation media containing 2 µM 
rapamycin while addressing the second microchannel with only MN differentiation media (0 µM rapamycin). 
Flow rate in each channel was kept constant at ~ 100 µl/hr for the duration of the experiments. This maintained 
a linear rapamycin gradient across the MN culture with 2 µM rapamycin at the high end and 0 µM rapamycin at 
the low end, thereby exposing MN cultures to a range of rapamycin concentrations in a single device. The precise 
concentration that each MN experiences is a function of its spatial position within the microdevice chamber.
Immunocytochemistry & western blotting. Following 7, 14, 21, 28 DIV, ES cell-derived motor neuron 
cultures were fixed using 4% paraformaldehyde in PBS for 10 min followed by several washes in PBS and incu-
bated with antibodies against TDP-43 (1:500; Proteintech # 66734-1-Ig), TDP-43 (1:500, Proteintech # 1078-2-
AP), ubiquitin (FK2 clone; 1:1000; MilliporeSigma # ST1200), GFP (1:500; Aves Labs, # 75-131), GFP (1:500; 
Sigma # A1112), Flag (1:500; Sigma # F3165), and FUS (1:500; Novus Biologicals # NB100-565) in PBS con-
taining 10% goat serum at 4° C overnight. The cells were subsequently washed with PBS, incubated with Alex 
Fluor 488, 594, 637 secondary antibodies (1:500; Invitrogen) at room temperature (RT) for 2 h, washed, and 
then mounted in VECTASHIELD antifade mounting medium (Vector Laboratories). 2D images were captured 
using a Leica confocal microscope (Leica). 3D images were captured using Axio Observer Z1 (Carl Zeiss, Inc.) 
inverted microscope at 5 × magnification. Using standard western blot protocols, lysates were prepared from 
MNs (control and mutant) collected on 7, 14, 21, and 28 DIV and assayed for Flag (Sigma # F3165) and TDP-
43 (Proteintech # 66734-1-Ig) proteins with β-tubulin as loading control. Blots were stripped and re-probed for 
each antibody against loading control.
Image analysis and quantification in microdevices. For image analysis and quantification, the 
chamber was divided vertically into ten 100 µm zones (permissive zones or bins) along the gradient. Each zone 
represents an average range of rapamycin concentration based on a linear concentration profile. Fluorescence 
intensity, corresponding to the number of positive cells (in our case, motor neurons) was plotted against the 
rapamycin concentration.  GFP+ cells were counted using ImageJ (NIH). As individual cells were not resolved at 
the low magnification (5x), fluorescent intensities were used to quantify cells. An ‘unsharp mask’ was applied, 
followed by cell count (particle analysis). A native eGFP response on 7DIV(day-7) was used as the baseline for 
GFP expression. ANOVA in conjunction with an appropriate multiple comparison test was performed for sta-
tistical significance (for a detailed comparison, see Sheet S1 ). A high resolution imaging for the localization of 
nuclear TDP-43 to that of cytoplasmic TDP-43 without destroying the positional construct (gradient zones) was 
not possible in the microdevice samples (Figs. 6, 7a). The reason for this is, high resolution images are rather 
difficult to obtain in thick 3D cultures, even using confocal or epifluorescence techniques due to constraints 
imposed by light scattering and absorptive processes. This, as well as the propensity of ESCs to cluster, is one 
of the disadvantages of the 3D microfluidic approach and why high-resolution images were only provided for 
the planar 2D cultures. A higher magnification image of a typical MN cluster in the microdevice showing their 
morphology is indicated in supplementary figure S4. This scattering/clustering does not preclude quantitative 
assessments of the total fluorescence or expression, which is the metric used in the 3D microdevice analysis as 
outlined and referenced in our previous  publication43.
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